Ruth Marise Elgamal

Ruth Marise Elgamal

Auto-generated profile, based on publicly available information

Ruth Marise Elgamal

University of California San Diego

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2025 in Science Advances
Verified
Journal Article
Open access
RMRebecca Melton
Rebecca Melton
SJSara Jimenez
Sara Jimenez
WEWeston Elison
Weston Elison
LTLuca Tucciarone
Luca Tucciarone
AHAbigail Howell
Abigail Howell
KGKyle J. Gaulton
Kyle J. Gaulton
Cell type–specific regulatory programs that drive type 1 diabetes (T1D) in the pancreas are poorly understood. Here, we performed single-nucleus multiomics and spatial transcriptomics in up to 32 nondiabetic (ND), autoantibody-positive (AAB + ), and T1D pancreas donors. Genomic profiles from 853,005 cells mapped to 12 pancreatic cell types, including multiple exocrine subtypes. β, Acinar, and other cell types, and related cellular niches, had altered abundance and gene activity in T1D progression, including distinct pathways altered in AAB + compared to T1D. We identified epigenomic drivers of gene activity in T1D and AAB + which, combined with genetic association, revealed causal pathways of T1D risk including antigen presentation in β cells. Last, single-cell and spatial profiles together revealed widespread changes in cell-cell signaling in T1D including signals affecting β cell regulation. Overall, these results revealed drivers of T1D in the pancreas, which form the basis for therapeutic targets for disease prevention.

16 March 2020 in Journal of the American Chemical Society
Verified
Journal Article
Open access
MLMiseon Lee
Miseon Lee
BMBasudeb Maji
Basudeb Maji
DMDebasish Manna
Debasish Manna
SKSevim Kahraman
Sevim Kahraman
RERuth M. Elgamal
Ruth M. Elgamal
ACAmit Choudhary
Amit Choudhary
The loss of insulin-producing β-cells is the central pathological event in type 1 and 2 diabetes, which has led to efforts to identify molecules to promote β-cell proliferation, protection, and imaging. However, the lack of β-cell specificity of these molecules jeopardizes their therapeutic potential. A general platform for selective release of small-molecule cargoes in β-cells over other islet cells ex vivo or other cell-types in an organismal context will be immensely valuable in advancing diabetes research and therapeutic development. Here, we leverage the unusually high Zn(II) concentration in β-cells to develop a Zn(II)-based prodrug system to selectively and tracelessly deliver bioactive small molecules and fluorophores to β-cells. The Zn(II)-targeting mechanism enriches the inactive cargo in β-cells as compared to other pancreatic cells; importantly, Zn(II)-mediated hydrolysis triggers cargo activation. This prodrug system, with modular components that allow for fine-tuning selectivity, should enable the safer and more effective targeting of β-cells.

20 November 2024 in The EMBO Journal
Verified
Journal Article
Open access
FQFahd Qadir
Fahd Qadir
RERuth M Elgamal
Ruth M Elgamal
KSKejing Song
Kejing Song
PKParul Kudtarkar
Parul Kudtarkar
SSSiva Sankara Vara Prasad Sakamuri
Siva Sankara Vara Prasad Sakamuri
FMFranck Mauvais-Jarvis
Franck Mauvais-Jarvis
Patients with type 2 and type 1 diabetes (T2D and T1D) exhibit sex-specific differences in insulin secretion, the mechanisms of which are unknown. We examined sex differences in human pancreatic islets from 52 donors with and without T2D combining single cell RNA-sequencing (scRNA-seq) and single nucleus ATAC-sequencing (snATAC-seq) with assays probing hormone secretion and bioenergetics. In non-diabetic (ND) donors, sex differences in islet cell chromatin accessibility and gene expression predominantly involved sex chromosomes. In contrast, islets from T2D donors exhibited similar sex differences in sex chromosome-encoded differentially expressed genes (DEGs) as ND donors, but also exhibited sex differences in autosomal genes. Comparing β cells from T2D and ND donors, gene enrichment of female β cells showed suppression in mitochondrial respiration, while male β cells exhibited suppressed insulin secretion, suggesting a role for mitochondrial failure in females in the transition to T2D. We finally performed cell type-specific, sex stratified, GWAS restricted to differentially accessible chromatin peaks across T2D, fasting glucose, and fasting insulin traits. We identified that differentially accessible regions overlap with T2D-associated variants in a sex- and cell type-specific manner.

1 November 2018 in Cell Reports
Verified
Journal Article
Open access
MKMiljan Kuljanin
Miljan Kuljanin
RERuth M. Elgamal
Ruth M. Elgamal
GBGillian I. Bell
Gillian I. Bell
DXDimetri Xenocostas
Dimetri Xenocostas
AXAnargyros Xenocostas
Anargyros Xenocostas
GLGilles A. Lajoie
Gilles A. Lajoie
Human multipotent stromal cells (hMSCs) are one of the most versatile cell types used in regenerative medicine due to their ability to respond to injury. In the context of diabetes, it has been previously shown that the regenerative capacity of hMSCs is donor specific after transplantation into streptozotocin (STZ)-treated immunodeficient mice. However, in vivo transplantation models to determine regenerative potency of hMSCs are lengthy, costly, and low throughput. Therefore, a high-throughput quantitative proteomics assay was developed to screen β cell regenerative potency of donor-derived hMSC lines. Using proteomics, we identified 16 proteins within hMSC conditioned media that effectively identify β cell regenerative hMSCs. This protein signature was validated using human islet culture assay, ELISA, and the potency was confirmed by recovery of hyperglycemia in STZ-treated mice. Herein, we demonstrated that quantitative proteomics can determine sample-specific protein signatures that can be used to classify previously uncharacterized hMSC lines for β cell regenerative clinical applications.

23 January 2019 in Stem Cells
Verified
Journal Article
Closed access
PDF file
MKMiljan Kuljanin
Miljan Kuljanin
RERuth M. Elgamal
Ruth M. Elgamal
GBGillian I. Bell
Gillian I. Bell
AXAnargyros Xenocostas
Anargyros Xenocostas
GLGilles A. Lajoie
Gilles A. Lajoie
DHDavid Hess
David Hess

6 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGShirin Geravandi
Shirin Geravandi
HLHuan Liu
Huan Liu
HPHeena Pahwa
Heena Pahwa
MMMurali Krishna Madduri
Murali Krishna Madduri
FAFarah Atawneh
Farah Atawneh
AAAmin Ardestani
Amin Ardestani
Type 1 diabetes (T1D) risk has been associated with enteroviral infections, particularly coxsackieviruses B (CVB). Cellular host factors contributing to virus-induced islet autoimmunity remain unclear. We show that the Hippo pathway effector Yes-associated Protein (YAP) is markedly upregulated in the exocrine and endocrine pancreas of T1D and at-risk autoantibody-positive (AAb+) donors, along with its target CTGF. YAP expression correlates with CVB RNA presence, often in or near infected cells. YAP overexpression enhances CVB replication, islet inflammation, and β-cell apoptosis, whereas its inhibition halts viral replication in primary and immortalized pancreatic cells. In exocrine-islet co-cultures, CVB triggers YAP and target gene expression. In mice, chronic β-cell YAP expression impairs glucose tolerance, abolishes insulin secretion, and promotes β-cell dedifferentiation. Mechanistically, YAP, in complex with its transcription factor TEAD, induces its own negative regulator MST1. MST1 inhibition boosts viral replication and reduces β-cell apoptosis, constituting a negative feedback loop in which the reciprocal antagonism between YAP and MST1 balances viral replication and β-cell death during CVB infections. YAP is thus an important host factor for enteroviral amplification, offering a potential antiviral target in T1D.